RTP Mobile Logo
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer (Webinar Video Proceedings)
Released January 2021

Featuring perspectives from Drs P Kelly Marcom, Joyce O’Shaughnessy and Hope S Rugo and Professor Peter Schmid. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

    LEARNING OBJECTIVES

    • Appreciate the biologic rationale for, available data with and potential long-term benefits of anti-PD-1/PD-L1 antibody therapy for patients with metastatic triple-negative breast cancer (TNBC).
    • Review available research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive TNBC, and use this information to identify patients who may be appropriate for this approach.
    • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure) and patient preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
    • Consider available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized TNBC, and consider the potential role of these strategies in clinical practice.
    • Assess the biologic rationale for ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for breast cancer, in order to effectively communicate the potential benefits of trial participation to patients.
    • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic breast cancer harboring BRCA1/2 mutations or other DNA repair pathway abnormalities, and consider the diagnostic and therapeutic implications for nonresearch care.
    • Recall the design of ongoing clinical trials evaluating other investigational PARP inhibitors and novel applications of PARP inhibitors alone or in combination with other systemic approaches (eg, immunotherapy, chemotherapy) for breast cancer, and counsel appropriate patients about availability and participation.
    • Understand the mechanisms of action of, early data with and ongoing research evaluating other novel agents and treatment strategies under development for TNBC.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.25 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SanAntonioBC20/TNBC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/SanAntonioBC20/TNBC/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SanAntonioBC20/TNBC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/SanAntonioBC20/TNBC.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    P Kelly Marcom, MD
    Director, Breast Oncology Program 
    Professor of Medicine
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Immunomedics Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, GlycoMimetics Inc, Novartis, Takeda Oncology, Verily; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.

    Joyce O'Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Grail Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seagen Inc, Syndax Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Novartis, Seagen Inc.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Consulting Agreements: Puma Biotechnology Inc, Samsung Bioepis; Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc.

    Professor Peter Schmid, MD, PhD
    Centre Lead
    Centre for Experimental Cancer Medicine
    Barts Cancer Institute
    London, United Kingdom

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc; Employment/Salary (Spouse): Roche Laboratories Inc. 

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, and Merck.

    Release date: January 2021
    Expiration date: January 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):